Skip to main content
Journal cover image

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.

Publication ,  Journal Article
Kam, YW; Kien, F; Roberts, A; Cheung, YC; Lamirande, EW; Vogel, L; Chu, SL; Tse, J; Guarner, J; Zaki, SR; Subbarao, K; Peiris, M; Nal, B; Altmeyer, R
Published in: Vaccine
January 2007

Vaccine-induced antibodies can prevent or, in the case of feline infectious peritonitis virus, aggravate infections by coronaviruses. We investigated whether a recombinant native full-length S-protein trimer (triSpike) of severe acute respiratory syndrome coronavirus (SARS-CoV) was able to elicit a neutralizing and protective immune response in animals and analyzed the capacity of anti-S antibodies to mediate antibody-dependent enhancement (ADE) of virus entry in vitro and enhancement of replication in vivo. SARS-CoV-specific serum and mucosal immunoglobulins were readily detected in immunized animals. Serum IgG blocked binding of the S-protein to the ACE2 receptor and neutralized SARS-CoV infection in vitro. Entry into human B cell lines occurred in a FcgammaRII-dependent and ACE2-independent fashion indicating that ADE of virus entry is a novel cell entry mechanism of SARS-CoV. Vaccinated animals showed no signs of enhanced lung pathology or hepatitis and viral load was undetectable or greatly reduced in lungs following challenge with SARS-CoV. Altogether our results indicate that a recombinant trimeric S protein was able to elicit an efficacious protective immune response in vivo and warrant concern in the safety evaluation of a human vaccine against SARS-CoV.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vaccine

DOI

EISSN

1873-2518

ISSN

0264-410X

Publication Date

January 2007

Volume

25

Issue

4

Start / End Page

729 / 740

Related Subject Headings

  • Virology
  • Viral Envelope Proteins
  • Spike Glycoprotein, Coronavirus
  • Severe acute respiratory syndrome-related coronavirus
  • Severe Acute Respiratory Syndrome
  • Receptors, IgG
  • Mice
  • Membrane Glycoproteins
  • Immunoglobulin G
  • Immunoglobulin A
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kam, Y. W., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., … Altmeyer, R. (2007). Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine, 25(4), 729–740. https://doi.org/10.1016/j.vaccine.2006.08.011
Kam, Yiu Wing, François Kien, Anjeanette Roberts, Yan Chung Cheung, Elaine W. Lamirande, Leatrice Vogel, Shui Ling Chu, et al. “Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.Vaccine 25, no. 4 (January 2007): 729–40. https://doi.org/10.1016/j.vaccine.2006.08.011.
Kam, Yiu Wing, et al. “Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.Vaccine, vol. 25, no. 4, Jan. 2007, pp. 729–40. Epmc, doi:10.1016/j.vaccine.2006.08.011.
Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, Subbarao K, Peiris M, Nal B, Altmeyer R. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007 Jan;25(4):729–740.
Journal cover image

Published In

Vaccine

DOI

EISSN

1873-2518

ISSN

0264-410X

Publication Date

January 2007

Volume

25

Issue

4

Start / End Page

729 / 740

Related Subject Headings

  • Virology
  • Viral Envelope Proteins
  • Spike Glycoprotein, Coronavirus
  • Severe acute respiratory syndrome-related coronavirus
  • Severe Acute Respiratory Syndrome
  • Receptors, IgG
  • Mice
  • Membrane Glycoproteins
  • Immunoglobulin G
  • Immunoglobulin A